MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ
0.8250
-0.0455
-5.23%
After Hours: 0.8256 +0.0006 +0.07% 19:56 12/05 EST
OPEN
0.9100
PREV CLOSE
0.8705
HIGH
0.9100
LOW
0.8220
VOLUME
586.14K
TURNOVER
--
52 WEEK HIGH
108.00
52 WEEK LOW
0.7106
MARKET CAP
4.84M
P/E (TTM)
-0.0211
1D
5D
1M
3M
1Y
5Y
1D
Salarius Pharmaceuticals, Texas Biomed collaborate on Avian Flu study
TipRanks · 5d ago
Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
Benzinga · 5d ago
SALARIUS PHARMACEUTICALS TO COLLABORATE WITH TEXAS BIOMEDICAL RESEARCH INSTITUTE ON AVIAN FLU STUDY
Reuters · 5d ago
Weekly Report: what happened at SLRX last week (1124-1128)?
Weekly Report · 5d ago
Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares
Reuters · 11/24 22:08
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Scientific Officer Barbara Louise Hibner
Reuters · 11/24 16:25
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Business Officer Peter Klaus Marschel
Reuters · 11/24 16:24
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce
Reuters · 11/24 16:23
More
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.

Webull offers Salarius Pharmaceuticals Inc stock information, including NASDAQ: SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.